硼替佐米联合沙利度胺在多发性骨髓瘤干细胞移植后的维持治疗:PETHEMA/GEM试验
III期GEM05MENOS65试验将390例65岁及以下新诊断症状性多发性骨髓瘤患者随机分配接受诱导治疗,随后行自体干细胞移植(ASCT)及MEL-200方案,移植后二次随机比较沙利度胺/硼替佐米(TV)、沙利度胺(T)和α-2b干扰素(alfa2-IFN)维持治疗;271例患者随机分组(TV组91例、T组88例、alfa2-IFN组92例)。中位随访58.6个月,TV组无进展生存期(PFS)显著长于T组和alfa2-IFN组(50.6 vs 40.3 vs 32.5个月,P=0.03),总生存期三组无显著差异。
要点
- TV组PFS显著长于T组和alfa2-IFN组(50.6 vs 40.3 vs 32.5个月,P=0.03)。
- 总生存期三组无显著差异。
- 2-3级周围神经病变发生率TV组48.8%、T组34.4%、alfa2-IFN组1%。
核心结论
- 硼替佐米联合沙利度胺维持治疗较沙利度胺或alfa2-IFN显著延长PFS。
研究设计与样本
- III期GEM05MENOS65试验将390例65岁及以下新诊断症状性多发性骨髓瘤患者随机分配接受沙利度胺/地塞米松、硼替佐米/沙利度胺/地塞米松和VBMCP/VBAD/B诱导治疗,随后行ASCT及MEL-200方案。
- 移植后二次随机比较TV、T和alfa2-IFN维持治疗,共271例患者随机分组(TV组91例、T组88例、alfa2-IFN组92例)。
- 维持治疗方案:TV组沙利度胺100 mg每日联合硼替佐米1.3 mg/m2静脉注射每3个月一周期(第1、4、8、11天给药);T组沙利度胺100 mg每日;alfa2-IFN组3 MU每周三次,持续至多3年。
主要发现
- 维持治疗后完全缓解率TV组提高21%、T组提高11%、alfa2-IFN组提高17%(P值未达显著)。
- 中位随访58.6个月,PFS在TV组显著长于T组和alfa2-IFN组(50.6 vs 40.3 vs 32.5个月,P=0.03)。
- 总生存期三组无显著差异。
- 2-3级周围神经病变发生率TV组48.8%、T组34.4%、alfa2-IFN组1%。
局限性
- 完全缓解率提高的P值未达显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phase III trial GEM05MENOS65 randomized 390 patients 65 years old or younger with newly diagnosed symptomatic multiple myeloma (MM) to receive induction with thalidomide/dexamethasone, bortezomib/thalidomide/dexamethasone and Vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone bortezomib (VBMCP/VBAD/B) followed by autologous stem cell transplantation (ASCT) with MEL-200. After ASCT, a second randomization was performed to compare thalidomide/bortezomib (TV), thalidomide (T) and alfa-2b interferon (alfa2-IFN). Maintenance treatment consisted of TV (thalidomide 100 mg daily plus one cycle of intravenous bortezomib at 1.3 mg/m2 on days 1, 4, 8 and 11 every 3 months) versus T (100 mg daily) versus alfa2-IFN (3 MU three times per week) for up to 3 years. A total of 271 patients were randomized (TV: 91; T: 88; alfa2-IFN: 92). The complete response (CR) rate with maintenance was improved by 21% with TV, 11% with T and 17% with alfa2-IFN (P, not significant). After a median follow-up of 58.6 months, the progression-free survival (PFS) was significantly longer with TV compared with T and alfa2-IFN (50.6 vs 40.3 vs 32.5 months, P=0.03). Overall survival was not significantly different among the three arms. Grade 2-3 peripheral neuropathy was observed in 48.8%, 34.4% and 1% of patients treated with TV, T and alfa2-IFN, respectively. In conclusion, bortezomib and thalidomide maintenance resulted in a significantly longer PFS when compared with thalidomide or alfa2-IFN. (no. EUDRA 2005-001110-41).
引用
- Rosiñol L, Oriol A, Teruel AI, et al. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Leukemia. 2017. PMID: 28111466. doi:10.1038/leu.2017.35
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。